Literature DB >> 19731617

Clinical assessment in the spondyloarthropathies.

Ruth Wittoek1, Herman Mielants.   

Abstract

In order to measure disease activity, progression and response to therapy, it is important to use accurate, reliable and feasible outcome measures that can ideally be used in longitudinal cohorts, clinical trials and clinical practice. With emerging therapies, the focus on the methodology of outcome assessment has increased to ensure that discriminant and responsive instruments are used. This chapter reviews available measures of three major areas of disease impact in the spondyloarthropathies (disease activity, structural damage and functioning) and discusses the relevance for use in clinical practice. First, the outcome measures available for the assessment of different domains in ankylosing spondylitis, composite-indices and response criteria for use in clinical trials and clinical practice in ankylosing spondylitis are discussed. Secondly, the performance of these in psoriatic arthritis and more disease-specific instruments in psoriatic arthritis are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19731617     DOI: 10.1007/978-1-4419-0298-6_1

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  1 in total

1.  Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis.

Authors:  Alberto Migliore; Emanuele Bizzi; Mauro Bernardi; Andrea Picchianti Diamanti; Bruno Laganà; Lea Petrella
Journal:  Clin Drug Investig       Date:  2015-01       Impact factor: 2.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.